EluSys Therapeutics Adds Business Development Pro; Signals Focus on Exploring Licensing and Co-Marketing Opportunities

Apr 23, 2001, 01:00 ET from EluSys Therapeutics, Inc.

    PINE BROOK, N.J. April 23 /PRNewswire Interactive News Release/ --
 EluSys Therapeutics, Inc., a biopharmaceutical company focused on treatments
 for blood-borne diseases, announced today that former Goldman Sachs vice
 president Cynthia Beach, Ph.D., has joined the company as vice president of
 business development.
     "Cynthia Beach has an impressive background that combines more than a
 decade of experience at pharmaceutical companies with a number of years
 working in the financial industry analyzing the healthcare sector," said
 Stephen Sudovar, president and CEO of EluSys.  "Her knowledge and her
 understanding of the leading companies in the pharmaceutical industry will
 provide EluSys with the capability to execute the necessary strategic
 collaborations to ensure our success.  We are very happy to have Dr. Beach on
 board."
 
     Cynthia Beach, Ph.D.
     Dr. Beach brings to EluSys nearly 25 years of experience in business
 development at investment firms and in the healthcare industry.  Previously,
 she was vice president of global equity research at Goldman Sachs, where she
 was a senior research analyst covering the U.S. pharmaceutical industry.
 Before this she was vice president of equity research at Gerard Klauer
 Mattison, following the healthcare industry.
     From the mid-80s to the mid-90s, Dr. Beach worked in the pharmaceutical
 industry, at Pfizer, Inc and Organon, Inc.  As director of licensing and
 development at Pfizer from 1991-1996,  she helped establish a worldwide
 strategic alliance with Eisai Co., Ltd. for the Alzheimer's drug Aricept and
 negotiated Pfizer's alliance on neutrophil inhibitory factor for stroke with
 Corvas International.
     "The Heteropolymer System EluSys is developing is a very exciting
 technology," commented Dr. Beach.  "Its broad application has tremendous
 potential for attracting pharmaceutical companies or even other biotech firms
 as marketing partners or licensees who want to apply the technology to their
 area of expertise."
 
     The Heteropolymer System:  "Biological Double-Sided Tape"
     The EluSys Heteropolymer (HP) System is a monoclonal antibody-based
 technology designed to enable the body to use its own red blood cells to
 efficiently remove and destroy a wide variety of blood-borne pathogens, toxins
 and autoantibodies.  The HP System uses a proprietary bi-specific monoclonal
 antibody (the Heteropolymer) which binds the target pathogen to red blood
 cells, like a piece of biological double-sided tape.  The red blood cells
 carry the Heteropolymer-pathogen complex to the liver, where it is destroyed.
     The HP System has been studied against ten different model or actual
 pathogens, including dengue virus, Pseudomonas aeruginosa (bacteria), E. coli
 (toxin) and autoantibodies involved in the autoimmune diseases myasthenia
 gravis and lupus.
     Experiments show that the HP System can clear even substantial levels of a
 variety of pathogens and autoantibodies from the bloodstream of nonhuman
 primates within an hour.  Other experiments have demonstrated that EluSys'
 Heteropolymers may prevent pathogens from ever reaching appreciable
 concentrations in the blood when injected before exposure.
 
     About EluSys
     EluSys Therapeutics, Inc. is a privately held biopharmaceutical company
 focused on developing treatments for a variety of blood-borne diseases.
 EluSys' patented monoclonal antibody-based technology, the Heteropolymer
 ("HP") System, may offer a significant advance in the management and treatment
 of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the
 effectiveness of the body's own natural defense mechanisms to remove such
 pathogens from the blood and destroy them.  EluSys recently signed a research
 agreement with the U.S. Army Medical Research Institute of Infectious Diseases
 (USAMRIID) to develop treatments for anthrax and other potential biowarfare
 agents.  Founded in 1998, EluSys is headquartered in Pine Brook, NJ.
 Additional information about EluSys, the HP technology and senior management
 can be found at http://www.EluSys.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X76951038
 
 

SOURCE EluSys Therapeutics, Inc.
    PINE BROOK, N.J. April 23 /PRNewswire Interactive News Release/ --
 EluSys Therapeutics, Inc., a biopharmaceutical company focused on treatments
 for blood-borne diseases, announced today that former Goldman Sachs vice
 president Cynthia Beach, Ph.D., has joined the company as vice president of
 business development.
     "Cynthia Beach has an impressive background that combines more than a
 decade of experience at pharmaceutical companies with a number of years
 working in the financial industry analyzing the healthcare sector," said
 Stephen Sudovar, president and CEO of EluSys.  "Her knowledge and her
 understanding of the leading companies in the pharmaceutical industry will
 provide EluSys with the capability to execute the necessary strategic
 collaborations to ensure our success.  We are very happy to have Dr. Beach on
 board."
 
     Cynthia Beach, Ph.D.
     Dr. Beach brings to EluSys nearly 25 years of experience in business
 development at investment firms and in the healthcare industry.  Previously,
 she was vice president of global equity research at Goldman Sachs, where she
 was a senior research analyst covering the U.S. pharmaceutical industry.
 Before this she was vice president of equity research at Gerard Klauer
 Mattison, following the healthcare industry.
     From the mid-80s to the mid-90s, Dr. Beach worked in the pharmaceutical
 industry, at Pfizer, Inc and Organon, Inc.  As director of licensing and
 development at Pfizer from 1991-1996,  she helped establish a worldwide
 strategic alliance with Eisai Co., Ltd. for the Alzheimer's drug Aricept and
 negotiated Pfizer's alliance on neutrophil inhibitory factor for stroke with
 Corvas International.
     "The Heteropolymer System EluSys is developing is a very exciting
 technology," commented Dr. Beach.  "Its broad application has tremendous
 potential for attracting pharmaceutical companies or even other biotech firms
 as marketing partners or licensees who want to apply the technology to their
 area of expertise."
 
     The Heteropolymer System:  "Biological Double-Sided Tape"
     The EluSys Heteropolymer (HP) System is a monoclonal antibody-based
 technology designed to enable the body to use its own red blood cells to
 efficiently remove and destroy a wide variety of blood-borne pathogens, toxins
 and autoantibodies.  The HP System uses a proprietary bi-specific monoclonal
 antibody (the Heteropolymer) which binds the target pathogen to red blood
 cells, like a piece of biological double-sided tape.  The red blood cells
 carry the Heteropolymer-pathogen complex to the liver, where it is destroyed.
     The HP System has been studied against ten different model or actual
 pathogens, including dengue virus, Pseudomonas aeruginosa (bacteria), E. coli
 (toxin) and autoantibodies involved in the autoimmune diseases myasthenia
 gravis and lupus.
     Experiments show that the HP System can clear even substantial levels of a
 variety of pathogens and autoantibodies from the bloodstream of nonhuman
 primates within an hour.  Other experiments have demonstrated that EluSys'
 Heteropolymers may prevent pathogens from ever reaching appreciable
 concentrations in the blood when injected before exposure.
 
     About EluSys
     EluSys Therapeutics, Inc. is a privately held biopharmaceutical company
 focused on developing treatments for a variety of blood-borne diseases.
 EluSys' patented monoclonal antibody-based technology, the Heteropolymer
 ("HP") System, may offer a significant advance in the management and treatment
 of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the
 effectiveness of the body's own natural defense mechanisms to remove such
 pathogens from the blood and destroy them.  EluSys recently signed a research
 agreement with the U.S. Army Medical Research Institute of Infectious Diseases
 (USAMRIID) to develop treatments for anthrax and other potential biowarfare
 agents.  Founded in 1998, EluSys is headquartered in Pine Brook, NJ.
 Additional information about EluSys, the HP technology and senior management
 can be found at http://www.EluSys.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X76951038
 
 SOURCE  EluSys Therapeutics, Inc.